OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a research report on Wednesday, November 13th.

OncoCyte Stock Down 3.0 %

NASDAQ OCX opened at $2.55 on Wednesday. OncoCyte has a one year low of $2.29 and a one year high of $4.34. The company has a 50-day simple moving average of $3.00 and a 200-day simple moving average of $2.98.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The company had revenue of $0.12 million during the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same period in the prior year, the firm posted ($0.57) EPS.

Insider Buying and Selling at OncoCyte

In other OncoCyte news, CFO Andrea S. James purchased 33,670 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the acquisition, the insider now directly owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This trade represents a 26.69 % increase in their position. The disclosure for this purchase can be found here. 1.58% of the stock is owned by company insiders.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC increased its position in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the period. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. 55.35% of the stock is currently owned by hedge funds and other institutional investors.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.